{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:21Z","timestamp":1793394501762,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Biol"],"DOI":"10.1038\/s42003-026-09998-w","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:35:27Z","timestamp":1775788527000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ferroptosis as a therapeutic vulnerability in ARID1A-deficient bladder cancer"],"prefix":"10.1038","volume":"9","author":[{"given":"Mengxue","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianbin","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyue","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefen","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0448-0094","authenticated-orcid":false,"given":"Cheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-6141-0037","authenticated-orcid":false,"given":"Chunming","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"9998_CR1","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis, A. T., Lec, P. M., Chamie, K. & Mshs, M. D. Bladder cancer: a review. JAMA 324, 1980\u20131991 (2020).","journal-title":"JAMA"},{"key":"9998_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"9998_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles, M. A. & Hurst, C. D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat. Rev. Cancer 15, 25\u201341 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"9998_CR4","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","volume":"388","author":"AM Kamat","year":"2016","unstructured":"Kamat, A. M. et al. Bladder cancer. Lancet 388, 2796\u20132810 (2016).","journal-title":"Lancet"},{"key":"9998_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3233\/BLC-160053","volume":"2","author":"SP Lerner","year":"2016","unstructured":"Lerner, S. P. et al. Summary and recommendations from the National Cancer Institute\u2019s clinical trials planning meeting on novel therapeutics for non-muscle invasive bladder cancer. Bladder Cancer 2, 165\u2013202 (2016).","journal-title":"Bladder Cancer"},{"key":"9998_CR6","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1038\/bjc.2014.633","volume":"112","author":"A Orsola","year":"2015","unstructured":"Orsola, A. et al. Reexamining treatment of high-grade T1 bladder cancer according to depth of lamina propria invasion: a prospective trial of 200 patients. Br. J. Cancer 112, 468\u2013474 (2015).","journal-title":"Br. J. Cancer"},{"key":"9998_CR7","first-page":"1435","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein, J. I., Amin, M. B., Reuter, V. R. & Mostofi, F. K. The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consens. Conf. Comm. Am. J. Surg. Pathol. 22, 1435\u20131448 (1998).","journal-title":"Bladder Consens. Conf. Comm. Am. J. Surg. Pathol."},{"key":"9998_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","volume":"70","author":"PA Humphrey","year":"2016","unstructured":"Humphrey, P. A., Moch, H., Cubilla, A. L., Ulbright, T. M. & Reuter, V. E. The 2016 WHO Classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur. Urol. 70, 106\u2013119 (2016).","journal-title":"Eur. Urol."},{"key":"9998_CR9","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch, H. et al. The 2022 World Health Organization Classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur. Urol. 82, 458\u2013468 (2022).","journal-title":"Eur. Urol."},{"key":"9998_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e525 (2017).","journal-title":"Cell"},{"key":"9998_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.urolonc.2010.04.008","volume":"28","author":"DJ McConkey","year":"2010","unstructured":"McConkey, D. J. et al. Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol. Oncol. 28, 429\u2013440 (2010).","journal-title":"Urol. Oncol."},{"key":"9998_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41571-020-0357-3","volume":"17","author":"P Mittal","year":"2020","unstructured":"Mittal, P. & Roberts, C. W. M. The SWI\/SNF complex in cancer\u2014biology, biomarkers and therapy. Nat. Rev. Clin. Oncol. 17, 435\u2013448 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"9998_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1158\/2159-8290.CD-12-0361","volume":"3","author":"JN Wu","year":"2013","unstructured":"Wu, J. N. & Roberts, C. W. ARID1A mutations in cancer: another epigenetic tumor suppressor?. Cancer Discov. 3, 35\u201343 (2013).","journal-title":"Cancer Discov."},{"key":"9998_CR14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.gdata.2015.06.027","volume":"5","author":"RL Chandler","year":"2015","unstructured":"Chandler, R. L., Raab, J. R., Vernon, M., Magnuson, T. & Schisler, J. C. Global gene expression profiling of a mouse model of ovarian clear cell carcinoma caused by ARID1A and PIK3CA mutations implicates a role for inflammatory cytokine signaling. Genom. Data 5, 329\u2013332 (2015).","journal-title":"Genom. Data"},{"key":"9998_CR15","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel, V. G., Oh, W. K. & Galsky, M. D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J. Clin. 70, 404\u2013423 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"9998_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217506","volume":"614","author":"MP Scholtes","year":"2025","unstructured":"Scholtes, M. P. et al. Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets. Cancer Lett. 614, 217506 (2025).","journal-title":"Cancer Lett."},{"key":"9998_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr","year":"2005","unstructured":"Kaelin, W. G. Jr The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689\u2013698 (2005).","journal-title":"Nat. Rev. Cancer"},{"key":"9998_CR18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-med-050913-022545","volume":"66","author":"CJ Lord","year":"2015","unstructured":"Lord, C. J., Tutt, A. N. & Ashworth, A. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu. Rev. Med. 66, 455\u2013470 (2015).","journal-title":"Annu. Rev. Med."},{"key":"9998_CR19","doi-asserted-by":"publisher","unstructured":"Chan, P. Y. et al. The synthetic lethal interaction between CDS1 and CDS2 is a vulnerability in uveal melanoma and across multiple tumor types. Nat. Genet. https:\/\/doi.org\/10.1038\/s41588-025-02222-1 (2025).","DOI":"10.1038\/s41588-025-02222-1"},{"key":"9998_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00850-8","volume":"9","author":"R Saito","year":"2025","unstructured":"Saito, R., Fukushima, M., Sasaki, M., Okamoto, A. & Ogiwara, H. Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma. NPJ Precis. Oncol. 9, 69 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"9998_CR21","doi-asserted-by":"publisher","unstructured":"Rehman, H. et al. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight 7 https:\/\/doi.org\/10.1172\/jci.insight.155899 (2022).","DOI":"10.1172\/jci.insight.155899"},{"key":"9998_CR22","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccell.2023.03.021","volume":"41","author":"S Jana","year":"2023","unstructured":"Jana, S. et al. Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression. Cancer Cell 41, 853\u2013870.e813 (2023).","journal-title":"Cancer Cell"},{"key":"9998_CR23","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ccell.2023.03.002","volume":"41","author":"W Zhou","year":"2023","unstructured":"Zhou, W. et al. Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis. Cancer Cell 41, 740\u2013756.e710 (2023).","journal-title":"Cancer Cell"},{"key":"9998_CR24","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"9998_CR25","doi-asserted-by":"publisher","first-page":"e02523","DOI":"10.7554\/eLife.02523","volume":"3","author":"SJ Dixon","year":"2014","unstructured":"Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 3, e02523 (2014).","journal-title":"Elife"},{"key":"9998_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/s41418-017-0012-4","volume":"25","author":"L Galluzzi","year":"2018","unstructured":"Galluzzi, L. et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 25, 486\u2013541 (2018).","journal-title":"Cell Death Differ."},{"key":"9998_CR27","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1073\/pnas.97.10.5101","volume":"97","author":"ZZ Shi","year":"2000","unstructured":"Shi, Z. Z. et al. Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proc. Natl. Acad. Sci. USA 97, 5101\u20135106 (2000).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9998_CR28","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1016\/j.freeradbiomed.2004.06.040","volume":"37","author":"TP Dalton","year":"2004","unstructured":"Dalton, T. P., Chen, Y., Schneider, S. N., Nebert, D. W. & Shertzer, H. G. Genetically altered mice to evaluate glutathione homeostasis in health and disease. Free Radic. Biol. Med. 37, 1511\u20131526 (2004).","journal-title":"Free Radic. Biol. Med."},{"key":"9998_CR29","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula, P., Zhuang, L. & Gan, B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell 12, 599\u2013620 (2021).","journal-title":"Protein Cell"},{"key":"9998_CR30","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/s41392-024-01969-z","volume":"9","author":"Q Ru","year":"2024","unstructured":"Ru, Q. et al. Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic prospects. Signal Transduct. Target Ther. 9, 271 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"9998_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang, W. S. et al. Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317\u2013331 (2014).","journal-title":"Cell"},{"key":"9998_CR32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000028396","volume":"61","author":"JD Hayes","year":"2000","unstructured":"Hayes, J. D. & Strange, R. C. Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61, 154\u2013166 (2000).","journal-title":"Pharmacology"},{"key":"9998_CR33","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.tips.2012.09.007","volume":"33","author":"B Wu","year":"2012","unstructured":"Wu, B. & Dong, D. Human cytosolic glutathione transferases: structure, function, and drug discovery. Trends Pharm. Sci. 33, 656\u2013668 (2012).","journal-title":"Trends Pharm. Sci."},{"key":"9998_CR34","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/sj.onc.1209373","volume":"25","author":"CC McIlwain","year":"2006","unstructured":"McIlwain, C. C., Townsend, D. M. & Tew, K. D. Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25, 1639\u20131648 (2006).","journal-title":"Oncogene"},{"key":"9998_CR35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2122840119","volume":"119","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11. Proc. Natl. Acad. Sci. USA 119, e2122840119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9998_CR36","doi-asserted-by":"publisher","first-page":"7369","DOI":"10.1038\/sj.onc.1206940","volume":"22","author":"DM Townsend","year":"2003","unstructured":"Townsend, D. M. & Tew, K. D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22, 7369\u20137375 (2003).","journal-title":"Oncogene"},{"key":"9998_CR37","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1083\/jcb.201804161","volume":"217","author":"A Bansal","year":"2018","unstructured":"Bansal, A. & Simon, M. C. Glutathione metabolism in cancer progression and treatment resistance. J. Cell Biol. 217, 2291\u20132298 (2018).","journal-title":"J. Cell Biol."},{"key":"9998_CR38","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1158\/0008-5472.CAN-20-3477","volume":"81","author":"A Ghoochani","year":"2021","unstructured":"Ghoochani, A. et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Res. 81, 1583\u20131594 (2021).","journal-title":"Cancer Res."},{"key":"9998_CR39","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/ng.3421","volume":"47","author":"GM DeNicola","year":"2015","unstructured":"DeNicola, G. M. et al. NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat. Genet. 47, 1475\u20131481 (2015).","journal-title":"Nat. Genet."},{"key":"9998_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101107","volume":"23","author":"M Dodson","year":"2019","unstructured":"Dodson, M., Castro-Portuguez, R. & Zhang, D. D. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol. 23, 101107 (2019).","journal-title":"Redox Biol."},{"key":"9998_CR41","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ng.3744","volume":"49","author":"R Mathur","year":"2017","unstructured":"Mathur, R. et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat. Genet. 49, 296\u2013302 (2017).","journal-title":"Nat. Genet."},{"key":"9998_CR42","doi-asserted-by":"publisher","first-page":"276","DOI":"10.18632\/aging.204481","volume":"15","author":"J He","year":"2023","unstructured":"He, J. et al. Effects of NBP on postoperative cognitive dysfunction in rats via Nrf 2\/ARE pathway. Aging 15, 276\u2013286 (2023).","journal-title":"Aging"},{"key":"9998_CR43","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/ncb2956","volume":"16","author":"K Shin","year":"2014","unstructured":"Shin, K. et al. Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma. Nat. Cell Biol. 16, 469\u2013478 (2014).","journal-title":"Nat. Cell Biol."},{"key":"9998_CR44","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ccell.2014.09.001","volume":"26","author":"K Shin","year":"2014","unstructured":"Shin, K. et al. Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors. Cancer Cell 26, 521\u2013533 (2014).","journal-title":"Cancer Cell"},{"key":"9998_CR45","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2017.08.007","volume":"32","author":"KJ Roberts","year":"2017","unstructured":"Roberts, K. J., Kershner, A. M. & Beachy, P. A. The stromal niche for epithelial stem cells: a template for regeneration and a brake on malignancy. Cancer Cell 32, 404\u2013410 (2017).","journal-title":"Cancer Cell"},{"key":"9998_CR46","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","volume":"173","author":"SH Lee","year":"2018","unstructured":"Lee, S. H. et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer. Cell 173, 515\u2013528.e517 (2018).","journal-title":"Cell"},{"key":"9998_CR47","doi-asserted-by":"publisher","unstructured":"Perlman, S., Anheim, M., Boesch, S., Lewis, J. H. & Lynch, D. R. Managing aminotransferase elevations in patients with friedreich ataxia treated with omaveloxolone: a review and expert opinion on use considerations. Neurol Ther. https:\/\/doi.org\/10.1007\/s40120-025-00752-8 (2025).","DOI":"10.1007\/s40120-025-00752-8"},{"key":"9998_CR48","doi-asserted-by":"publisher","first-page":"9964","DOI":"10.1073\/pnas.1913633117","volume":"117","author":"D Yu","year":"2020","unstructured":"Yu, D. et al. Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proc. Natl. Acad. Sci. USA 117, 9964\u20139972 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"9998_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ccell.2014.11.019","volume":"27","author":"IS Harris","year":"2015","unstructured":"Harris, I. S. et al. Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27, 211\u2013222 (2015).","journal-title":"Cancer Cell"},{"key":"9998_CR50","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","volume":"35","author":"H Ogiwara","year":"2019","unstructured":"Ogiwara, H. et al. Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell 35, 177\u2013190.e178 (2019).","journal-title":"Cancer Cell"},{"key":"9998_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li, J. et al. Ferroptosis: past, present and future. Cell Death Dis. 11, 88 (2020).","journal-title":"Cell Death Dis."},{"key":"9998_CR52","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang, X., Stockwell, B. R. & Conrad, M. Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol. 22, 266\u2013282 (2021).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"9998_CR53","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini, C., Harris, I. S. & Mak, T. W. Modulation of oxidative stress as an anticancer strategy. Nat. Rev. Drug Discov. 12, 931\u2013947 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"9998_CR54","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/s42003-023-05477-8","volume":"6","author":"Q Sun","year":"2023","unstructured":"Sun, Q. et al. Cholesterol mediated ferroptosis suppression reveals essential roles of Coenzyme Q and squalene. Commun. Biol. 6, 1108 (2023).","journal-title":"Commun. Biol."},{"key":"9998_CR55","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","volume":"5","author":"J Shen","year":"2015","unstructured":"Shen, J. et al. ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discov. 5, 752\u2013767 (2015).","journal-title":"Cancer Discov."},{"key":"9998_CR56","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/ncb3064","volume":"16","author":"JP Friedmann Angeli","year":"2014","unstructured":"Friedmann Angeli, J. P. et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat. Cell Biol. 16, 1180\u20131191 (2014).","journal-title":"Nat. Cell Biol."},{"key":"9998_CR57","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-019-1707-0","volume":"575","author":"S Doll","year":"2019","unstructured":"Doll, S. et al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature 575, 693\u2013698 (2019).","journal-title":"Nature"},{"key":"9998_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100814","volume":"31","author":"M Conde","year":"2022","unstructured":"Conde, M. & Frew, I. J. Therapeutic significance of ARID1A mutation in bladder cancer. Neoplasia 31, 100814 (2022).","journal-title":"Neoplasia"},{"key":"9998_CR59","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature12912","volume":"505","author":"MS Lawrence","year":"2014","unstructured":"Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495\u2013501 (2014).","journal-title":"Nature"},{"key":"9998_CR60","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41588-024-02015-y","volume":"57","author":"N Wang","year":"2025","unstructured":"Wang, N. et al. Loss of Kmt2c or Kmt2d primes urothelium for tumorigenesis and redistributes KMT2A-menin to bivalent promoters. Nat. Genet. 57, 165\u2013179 (2025).","journal-title":"Nat. Genet."},{"key":"9998_CR61","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-025-02296-7","volume":"10","author":"D Yu","year":"2025","unstructured":"Yu, D. et al. Acevaltrate as a novel ferroptosis inducer with dual targets of PCBP1\/2 and GPX4 in colorectal cancer. Signal Transduct. Target Ther. 10, 211 (2025).","journal-title":"Signal Transduct. Target Ther."}],"container-title":["Communications Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09998-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09998-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:03:11Z","timestamp":1780963391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s42003-026-09998-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9998"],"URL":"https:\/\/doi.org\/10.1038\/s42003-026-09998-w","relation":{},"ISSN":["2399-3642"],"issn-type":[{"value":"2399-3642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"12 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"776"}}